Biotech Overbought Stocks: Agenus Inc. (NASDAQ:AGEN), Biota Pharmaceuticals (NASDAQ:BOTA), Albany Molecular Research (NASDAQ:AMRI), Sunesis Pharmaceuticals (NASDAQ:SNSS)

Technology Stocks News 10

Agenus Inc. (NASDAQ:AGEN) will release its fourth quarter and year end 2013 financial results before the market opens on March 5, 2014. Agenus Inc. (NASDAQ:AGEN) stock performance was 0.00% in last session and finished the day at $4.89. Traded volume was 0.00 shares in the last session and the average volume of the stock remained 1.12 million shares. The beta of the stock remained 1.33. Agenus Inc. (NASDAQ:AGEN) insider ownership is 3.10%.

Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) rose 0.76% to $6.62 yesterday on volume of 0.00 shares. The intra-day range of the stock was $6.42 – $6.71. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) has a market capitalization of 187.29 million.

FirstLight Fiber, a facilities-based telecommunications service provider operating fiber optic networks in Upstate New York and Northern New England with connectivity to Canada, announced today that Albany. Albany Molecular Research, Inc. (NASDAQ:AMRI)’s stock on February 28, 2014 reported a lower of -2.92% to the closing price of $15.60. Its fifty two weeks range is $7.76 – $16.38. The total market capitalization recorded 500.54 million. The overall volume in the last trading session was 0.00 shares. In its share capital, Albany Molecular Research, Inc. (NASDAQ:AMRI) has 32.09 million outstanding shares.

Sunesis Pharmaceuticals announced that it will host a conference call on Thursday, March 6, 2014 at 11:00 a.m. On Friday, shares of Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) advanced 2.02% to close the day at $6.55. Company return on investment (ROI) is -95.30% and its monthly performance is recorded as 49.20%. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) quarterly revenue growth is 27.68%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone